MaxCyte, Inc. CARMA Cell Therapies at SITC 2020 (6703E)
November 09 2020 - 8:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6703E
MaxCyte, Inc.
09 November 2020
CARMA Cell Therapies(TM) to Share Results of In-vitro
Characterization
of MCY-M11 at SITC 2020 Annual Meeting
Gaithersburg, Maryland - 9 November 2020: MaxCyte, Inc. (LSE:
MXCT, MXCL), a global cell-based therapies and life sciences
company, announces that its subsidiary CARMA Cell Therapies will
share results of a detailed phenotypic and functional
characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC cell
therapy candidate, at the Society for Immunotherapy of Cancer's
(SITC) 35(th) anniversary meeting. The Virtual Scientific Program
begins today and runs through to November 14, 2020.
The ePoster (Abstract# 108) entitled, "MCY-M11, a CAR-PBMC cell
product transiently expressing a mesothelin targeted mRNA CAR,
exhibits desirable functional and immune phenotype attributed to
sustained antitumor immunity in vitro," will be presented during
SITC's Poster Symposium with a live Q&A on Thursday, November
12 from 4:50-5:20 p.m. EST and on Saturday, November 14 from
1:00-1:30 p.m. EST.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy
candidate manufactured using unstimulated peripheral blood
mononuclear cells (PBMCs). MCY-M11 is under Phase I clinical
evaluation for the treatment of advanced ovarian cancer and
malignant peritoneal mesothelioma.
"We are encouraged by these in vitro findings, which demonstrate
MCY-M11's potential to enable a long-term antitumor response. This
work brings us one step closer to understanding the mechanism of
action of MCY-M11 and provides strong non-clinical rationale for
its use as a cancer cell therapy," said Dhana Chinnasamy, VP of
Non-Clinical and Translational Studies at CARMA.
For more information about the SITC Virtual Scientific Program
and to access the abstract, please visit: https://www.sitcancer.org
.
About MCY-M11
MCY-M11 is a non-viral, mRNA-based anti-mesothelin CAR-PBMC cell
therapy manufactured using un-manipulated peripheral blood
mononuclear cells (PBMC). It is being evaluated in the clinic as
treatment for high mesothelin expressing solid tumors. It is under
ongoing development in a first-in human multi-center,
non-randomized, open label, dose-escalation Phase I clinical trial
evaluating the safety and preliminary efficacy of intraperitoneal
infusions of MCY-M11 in individuals with platinum-resistant,
high-grade, serous adenocarcinoma of the ovary, primary peritoneum
or fallopian tube, or individuals with advanced peritoneal
mesothelioma, with recurrence after prior chemotherapy.
Interim results presented at the ASCO 2020 meeting show that
intraperitoneal infusion of MCY-M11 is feasible, safe, and well
tolerated. There have been no dose-limiting toxicities and no
treatment related discontinuations or deaths and most reported
treatment related adverse events have been Grades 1-2 per NCI CTCAE
in three completed dose levels as a single agent in the existing
cohort.
Enrollment in the fourth dose level of the existing cohort is in
progress and will run alongside with enrollment in the new parallel
cohort that includes a preconditioning regimen. Multiple cycles of
treatment will be allowed in both the fourth dose level of the
existing cohort and at all dose levels in the new parallel
preconditioning cohort.
More information about the study can be found at
ClinicalTrials.gov (Identifier: NCT03608618).
About CARMA Cell Therapies
Through its wholly owned subsidiary, CARMA Cell Therapies,
MaxCyte is facilitating advancement of novel mRNA-based cell
therapies for cancer and other diseases with serious unmet needs.
MaxCyte has developed CARMA(TM), a novel and proprietary platform
for the development of non-viral, human messenger RNA (mRNA)-based,
chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected
immune cell therapies. CARMA [derived from CAR mRNA] utilizes
MaxCyte's Flow Electroporation(R) technology for highly efficient,
non-viral, delivery of one or more mRNA(s) into un-manipulated
peripheral blood mononuclear cells (PBMCs) or isolated immune cells
such as T- or NK-cells. CARMA offers the potential for a safer cell
therapy, as a result of transient expression of receptor(s) and a
non-viral delivery approach. Together, CARMA and MaxCyte's
ExPERT(R) family of instruments also offer the potential for a
significantly streamlined, scalable, and cost-effective GMP
manufacturing process without the complexity of virus-based
products. At the start of 2020, MaxCyte established CARMA Cell
Therapies as a wholly owned subsidiary to facilitate independent
investment and new partnerships to advance the CARMA platform.
MaxCyte has retained Locust Walk, a global life science strategic
advisory and transaction firm. For more information, visit
/carma-cell-therapies/ .
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBGBDBBDGDGGC
(END) Dow Jones Newswires
November 09, 2020 08:00 ET (13:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024